hVIVO (LON:HVO) Shares Down 46.3% - Here's What Happened

hVIVO plc (LON:HVO - Get Free Report)'s share price traded down 46.3% during mid-day trading on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares were traded during mid-day trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Upgrades and Downgrades

Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a report on Friday, May 30th.

hVIVO Stock Down 0.3%

The company has a market cap of £73.38 million, a price-to-earnings ratio of 4.28 and a beta of 0.97. The stock has a 50-day simple moving average of GBX 15.98 and a 200-day simple moving average of GBX 17.81. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, analysts predict that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Transactions at hVIVO

In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($703,774.26). Corporate insiders own 14.03% of the company's stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.